Impact of primary medical or surgical therapy on prolactinoma patients’ BMI and metabolic profile over the long-term

Lukas Andereggen a,b,*, Janine Frey c, Robert H. Andres b, Markus M. Luedi d, Jan Gralla c, Gerrit A. Schubert a, Jürgen Beck f, Luigi Mariani g, Emanuel Christ h

a Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland
b Faculty of Medicine, University of Bern, Bern, Switzerland
c Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland
d Department of Gynecology and Obstetrics, Kantonsspital Lucerne, Lucerne, Switzerland
e Department of Neurosurgery, Medical Center, University of Freiburg, Freiburg, Germany
f Department of Neurosurgery, University Hospital of Basel, Basel, Switzerland
g Department of Endocrinology, Diabetes and Metabolism, University Hospital of Basel, Basel, Switzerland
h Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Switzerland

ARTICLE INFO
Keywords:
BMI
Dopamine agonist
Metabolic profile
Prolactinoma
Surgery

ABSTRACT
Objectives: High prolactin levels have been associated with weight gain and impaired metabolic profiles. While treatment with dopamine agonists (DAs) has been shown to improve these parameters, there is a lack of surgical series on its comparative effect in prolactinoma patients.

Methods: In this retrospective, comparative study, consecutive patients with a prolactinoma were enrolled if treated with first-line transsphenoidal surgery (TSS) or with DAs. Patients with prolactinomas of Knosp grade ≥2 and those with a follow-up < 24 months were excluded, as were patients with missing laboratory metabolic parameters at baseline and over the long-term. Effects of either treatment on BMI and the metabolic profile were analyzed, and independent risk factors for long-term obesity were calculated.

Results: Primary treatment was TSS for 12 patients (40%) and DAs for 18 patients (60%). At diagnosis, no significant differences between the two cohorts were observed with regard to adenoma size, Knosp grading, baseline prolactin (PRL) levels, prevalence of hypogonadism, or laboratory metabolic parameters. Mean follow-up was 51.9 months (range, 24–158). Over the long-term, both TSS and DAs led to the control of hyperprolactinemia (92% vs. 72%) and hypogonadism (78% vs. 83%) in the majority of patients. While a significant decrease in patients’ BMI and fasting glucose were observed, changes in the lipid profile were marginal and independent of the treatment modality. At baseline, increased BMI—but not the primary treatment strategy—was an independent predictor of long-term obesity.

Conclusions: Over the long-term, patients’ BMI and FG improve, but changes in the metabolic profile are marginal and independent of the primary treatment. It is presumable that not DAs per se, but rather the control of hyperprolactinemia plays a role in patients’ metabolic profile alterations.

Introduction

Obesity represents a global epidemic with increased morbidity and mortality [1]. Endocrine disorders, in particular Cushing’s syndrome, hyperprolactinaemia-induced hypogonadism, acromegaly and hypothyroidism have been associated with weight gain and exacerbated metabolic dysfunction [2,3]. The relationship between the metabolic syndrome and hyperprolactinaemia suggests that prolactin (PRL) may be per se a modulator of body weight [4]. Prolactinoma is a frequent source of hyperprolactinaemia and represents the most common hormone-secreting pituitary tumour [5]. While dopamine agonists (DAs) are the first-line approach [6–8], transsphenoidal surgery (TSS) has increasingly emerged as an alternative treatment option [9–11]. Reasons include the need for ongoing DA therapy in up to four fifths of patients and potential adverse medical effects over the long-term [12–16].

Improvement of the metabolic profile in prolactinoma patients has

* Corresponding author at: Department of Neurosurgery Kantonsspital Aarau 5000 Aarau, Switzerland. Tel.: +41 62 838 66 90. Fax.: +41 62 838 66 29.
E-mail address: lukas.andereggen@ksa.ch (L. Andereggen).

https://doi.org/10.1016/j.jcte.2021.100258
Received 27 May 2021; Accepted 9 June 2021
Available online 17 June 2021
2214-6237/© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
been attributed to DA therapy per se [17–19]. Currently, there is a paucity of data on the comparative impact of first-line surgery on prolactinoma patients’ body mass index (BMI) and metabolic profile.

In this cross-sectional long-term follow-up study, we aimed at analyzing the effect of either treatment approach in a matched cohort of patients, based on their BMI, glucose and lipid profiles.

Methods

Study design

This is a retrospective comparative analysis of a prospectively maintained database. We reviewed records from prolactinoma patients consecutively treated by either TSS or DAs as first-line therapy between January 1997 and December 2015. Clinical and laboratory metabolic parameters were assessed at baseline and over the long-term (>2 years). All patients fulfilled the diagnostic criteria of having a PRL-secreting pituitary adenoma [20]. The Human Research Ethics Committee of Bern (Kantonale Ethikkommission KEK Bern, Bern, Switzerland) approved the study (KEK n° 10-10-2006 and 8-11-2006).

Inclusion and exclusion criteria

A flow chart of the patient selection process is depicted in Fig. 1. Patients with mixed-secreting adenomas, or those with secondary hyperprolactinemia due to antidepressants, opiates or neuroleptics, were excluded from the analysis. There were 84 patients treated by TSS and 78 patients treated with DAs. Patients with missing metabolic parameters at baseline and at last follow-up were excluded (n = 73). The same was true for patients with a follow-up < 24 months (n = 21) or those with prolactinomas of a Knosp grade ≥ 2 (n = 22). The latter was done to prevent any selection bias towards medical therapy in prolactinomas infiltrating the cavernous sinus [21].

Biochemical assessment

The following metabolic parameters were measured after an overnight fast: glucose (i.e., fasting glucose, FG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) concentrations. Impaired fasting glucose (IFG) was defined as FG values between 6.1 and 6.9 mmol/l. PRL levels, including the immunoradiometric PRL assay with serum dilution in order to overcome the high-dose PRL hook effect [22–23], and pituitary axis deficits were assessed. The upper limit of the PRL level was 25 µg/L for women and 20 µg/L for men [24]. Impaired secretion of one or more pituitary hormones was indicative of hypopituitarism. Secondary adrenal insufficiency was defined by the presence of low serum cortisol levels (<50 nmol/L) or normal cortisol but inadequate responses to the adrenocorticotropic (ACTH) stimulation test or insulin tolerance test. Secondary hypothyroidism was defined as low-normal thyroid-stimulating hormone (TSH) levels and a low free thyroxin (FT4) level. A gonadotropin deficiency or central hypogonadism was defined as low-normal levels of gonadotropins in parallel with low total estradiol/testosterone levels. Immunohistochemical analysis according to the WHO classification for neuroendocrine tumors was confirmed in the surgical cohort [25].

Assessment of BMI

Standard BMI was calculated for all patients [26]. A BMI of 21–25 kg/m² was considered normal. BMI 26–30 kg/m² was overweight, and BMI > 30 kg/m² was obese.

Radiological assessment

A conventional 1.5-T or 3-Tesla pituitary MRI was conducted at diagnosis and at follow-up. The standard protocol included a proton density/T2-weighted whole-brain scan with 5 mm slice thickness and both unenhanced and contrast-enhanced overlapping 3 mm scans in the sagittal and coronal planes over the sellar region, as previously reported [21,27]. An adenoma with a diameter of 1–10 mm was defined as a microadenoma and an adenoma ≥10 mm as a macroadenoma. Infiltration of the cavernous sinus was recorded according to the Knosp classification [28–29].

Treatment modalities for prolactinomas

Treatment options were discussed at the weekly interdisciplinary pituitary board meeting. Surgery was considered for prolactinomas not extending beyond the medial carotid line (i.e., Knosp grade ≤1) [21,30].

---

Fig. 1. Flow chart of patient selection process Out of 162 patients with a prolactinoma, first therapy was TSS in 84 patients and DA in 78 patients. 30 patients met the final inclusion criteria.
The indication for first-line surgery was further discussed with the patient. Based on his/her preferences, medical therapy was initiated or surgery was performed. Types of DA-agonists, maximal doses, and duration of treatment were noted (e.g., bromocriptine, and cabergoline). In Switzerland, both treatment options are covered by health insurance, so cost should not be a factor in the choice of treatment. In the surgical cohort, pituitary surgery was performed using a transsphenoidal, trans-sphenoidal microsurgical approach (i.e., TSS) with sellar reconstruction to prevent cerebrospinal fistula, as previously described [9,10,31–34].

Long-term assessment

If PRL levels had normalized and a tumor reduction of >50% was attained at the time of radiological follow-up, DAs were tapered 24 months after initiation of the medical therapy [35–36]. Recurrence was defined as an increase in PRL levels above the normal range (>25 µg/L for women, >20 µg/L for men) during the last follow-up period after a previous remission, irrespective of radiological findings [37–38].

Statistical analysis

Data were analyzed using IBM SPSS statistical software Version 24.0 (IBM Corp., New York, NY, USA) and GraphPad Prism (V7.04 software, San Diego, CA, USA). Continuous variables were examined for homogeneity of variance and are expressed as mean ± SD unless otherwise noted. Serum PRL levels are presented as median values and interquartile range (IQR). Categorical variables are given as numbers and percentages. For comparisons of means between groups, Student’s t-test was used for normally distributed data, and the Mann–Whitney test for nonparametric data (i.e., FG, HDL-C, and TG levels). The Wilcoxon signed-rank test was used to evaluate paired differences in PRL levels before and after treatment. Categorical variables were compared using Pearson’s chi-square test or Fisher’s exact test, as appropriate. Odds ratios (ORs) and 95% confidence intervals (CIs) of independent factors for obesity at last follow-up were analyzed by univariable and multivariable logistic regression. The variables tested were: age at diagnosis, sex, patient’s BMI (kg/m²), PRL levels at baseline, the primary treatment (i.e., DA), hypogonadism, and follow-up time. The multivariable logistic regression analysis included all dependent risk factors in the univariable regression with a p value ≤ 0.3. Baseline PRL values were log transformed before being imputed in the regression analysis, as data showed a positively skewed distribution. Significance level was set at < 0.05.

Results

Baseline characteristics

Among all patients treated for prolactinomas at our institution in the study period, 13 women and 17 men fulfilled the study inclusion criteria. Baseline characteristics of patients are detailed in Table 1. First therapy was TSS in 12 patients (40%) and DA in 18 (60%). No significant differences between the two cohorts were observed with regard to prevalence of a macroadenoma, the presence of a Knosp grade 1 adenoma, baseline PRL levels, affected pituitary axes including the prevalence of hypogonadism, or the metabolic profile (i.e., glucose and lipid concentrations).

Patients with a macroprolactinoma vs. those with a micro-prolactinoma showed significant differences in their BMI (31.5 ± 4.4 vs. 26.8 ± 7.5, p = 0.04, Fig. 2A) and HDL-C levels (1.1 ± 0.2 vs. 1.4 ± 0.6; p = 0.02), while no significant differences were noted with regard to LDL-C (p = 0.35), TC (p = 0.98), TG (p = 0.09), or FG levels (p = 0.24). In addition, a significant positive correlation between all patients’ PRL and BMI values (r = 0.4, p = 0.03, Fig. 2B) was observed. Likewise, there was a significant correlation in all patients between the prevalence of hypogonadism and HDL-C levels (r = −0.48, p = 0.007), as well as TG levels (r = 0.52, p = 0.004).
Scatterplot showing a significant positive correlation between all patients for cabergoline.

While none of these patients were taking bromocriptine, mean (±SD) doses at last follow-up were 3.9 ± 1.0 mg for cabergoline, and 35 mg (range 3–64 mg) for cabergoline.

At last follow-up, 6 patients (20%) were treated with statins; 3 (17%) in the medical cohort and 3 (25%) in the surgical cohort (p = 0.66). Levels of LDL-C (2.5 ± 1.1 vs. 3.4 ± 1.0; p = 0.07), TC (4.0 ± 1.2 vs. 5.0 ± 1.1; p = 0.09), and TG (1.3 ± 0.5 vs. 1.2 ± 0.4; p = 0.69) were lower in the statin cohort, though not significantly.

Metabolic impact of surgery or DAs as first-line treatment

The impact of TSS or DAs per se on patients’ metabolic profile is summarized in the supplementary tables (Tables S1 and S2). Surgery per se significantly decreased levels of TG (p = 0.02) and FG (p = 0.04), whereas DAs significantly decreased levels of TC (p = 0.05) and FG (p = 0.05). Net changes in patients’ BMI or PRL levels over the long-term were not significantly different between the two cohorts (i.e., TSS vs. DAs, Table S3).

With regard to the DA being used, cabergoline was more frequently prescribed than bromocriptine. Bromocriptine doses ranged from 2.5 to 10 mg/day, whereas cabergoline doses ranged from 0.5 to 2 mg/week.

In the medical cohort, DAs were required in 16 patients (53%) at last follow-up, with bromocriptine being noted in 5 (16%) and cabergoline in 11 (37%). Thereby, mean (±SD) doses at last follow-up were 3.9 ± 3.4 mg for bromocriptine (daily), and 1.3 ± 1.0 mg for cabergoline (weekly). Mean cumulative doses per patient at last follow-up were 971 mg (range 312–2340 mg) for bromocriptine, and 35 mg (range 3–80 mg) for cabergoline.

In the surgical cohort, cabergoline was required in 5 patients (17%) at last follow-up. While none of these patients were taking bromocriptine, mean (±SD) doses for cabergoline (weekly) were 1.1 ± 0.3 mg. Mean cumulative doses per patient were 28 mg (range 3–64 mg) for cabergoline.

Table 2
Long-term changes in metabolic parameters following treatment of hyperprolactinaemia.

|                  | All patients | Baseline | Long-term FU | p value |
|------------------|-------------|----------|--------------|---------|
| Prolactin (μg/L) | 856 (154–6473) | 11 (4–25) | 0.01         |
| BMI (kg/m2)      |             | 28.6 ± 6 | 26.5 ± 6     | 0.05    |
| Triglycerides (mmol/L) | 1.6 ± 1.1 | 1.1 ± 0.4 | 0.02         |
| HDL-cholesterol (mmol/L) | 1.2 ± 0.4 | 1.3 ± 0.4 | 0.18         |
| LDL-cholesterol (mmol/L) | 3.6 ± 0.8 | 3.4 ± 1.0 | 0.07         |
| Fasting glucose (mmol/L) | 5.4 ± 1.1 | 5.2 ± 0.7 | 0.01         |

BMI, body mass index; SD, standard deviation.

Morbidity and mortality

No mortality has been noted. In the surgical cohort, postoperative complications consisted of transient diabetes insipidus in one patient. In the medical group, prolonged nausea and vertigo were noted in one patient.

Discussion

The present analysis significantly adds to the existing literature on the comparative effect of first-line surgery and medical therapy on prolactinoma patients’ BMI and metabolic profile. Our long-term results indicate that i) hyperprolactinaemia and associated hypogonadism can be controlled in the majority of patients regardless of the primary treatment, ii) normalization of PRL improves patients’ BMI and FG levels, iii) marginal changes in patients’ metabolic profiles are noted, and iv) high baseline BMI but not the first therapy is a risk for persistent long-term obesity.

Impact on patients’ BMI

Prolactinoma patients display higher BMI and increased prevalence of obesity compared to the general population [17,39]. While we noted a significant correlation between BMI and PRL levels, corroborating recent results [39], the role of PRL in the pathophysiology of obesity remains unclear. Decreases in patients’ BMI levels are not an uncommon phenomenon following the control of hyperprolactinaemia [4,40]. DAs have been found to reduce body weight, particularly in patients with high baseline PRL levels [19,41–42]. Interestingly, we noted that normalization of PRL improves patients’ BMI, with a significant reduction in the TSS but not the DA cohort. Although PRL levels in both cohorts were not significantly different over the long-term, it is presumable that not DAs per se, but rather the control of hyperprolactinaemia and hypogonadism might account for this effect. Namely, the association between BMI and PRL levels has been noted [39]. Similarly, our findings indicate a significantly higher BMI in patients with a macroprolactinoma compared to those with a microprolactinoma, corroborating previous results [43]. It is conceivable that longer exposure to increased PRL levels, as occurs in men, affords for the true effect. Namely, while amenorrhea in women is easily detected and investigated, men often do not report the non-specific symptoms of hypogonadism, such as loss of libido. Consequently, men suffer from hyperprolactinemia and hypogonadism over a much longer period, a reason that macroprolactinomas are more commonly seen in them [44–45]. Whether hypogonadism and its associated lack of energy...
and physical exercise contributes to the increased BMI in females and males remains speculative. Increased BMI could also be related to an increase in adenoma-associated hypothalamic pressure rather than the effect of hyperprolactinemia itself, but this mechanism might only be valid in solid and large adenomas [46–47]. Finally, regardless of how hyperprolactinemia influences patients’ BMI [43], control of hyperprolactinemia is key in overweight prolactinoma patients.

Impact on patients’ FG profile

It has been hypothesized that DAs directly decrease the level of FG in obese patients [48–49]. Likewise, Pala et al. described a significant reduction in FG levels following treatment with Das [50], in keeping with our data showing significantly improved FG levels after DA therapy, but also after TSS. In contrast, Schwetz et al. did not confirm the previously described changes in the normalization of the glucose metabolism by Das [18]. This is of interest, given the postulated association between high PRL levels and an adverse glucose profile [51–52]. Yet, FG may independently improve based on a decrease in PRL levels and/or changes in BMI [53]. This corroborates the hypothesis that DAs alter the glucose metabolism by fortifying the suppression of endogenous glucose production, or enhancing the splanchnic glucose uptake, or through direct hypothalamic alterations [54]. These mechanisms were demonstrated by the use of quick-release bromocriptin in obese type 2 diabetic patients [54,55]. The same effect is associated with cabergoline therapy [17]. This would not explain why changes were also observed in our study cohort following TSS, but it affirms the importance of controlling hyperprolactinemia over the long-term.

Impact on patients’ lipid profiles

The proposed direct effect of DA therapy on the metabolic profile is debatable, and might rather be caused by the control of hyperprolactinemia and associated hypogonadism over the long-term. Namely, we observed that restoration of normoprolactinaemia and hypogonadism using either treatment led to a significant decrease in TG and TC levels, with no significant changes in LDL-C or HDL-C. Cross-sectional studies have shown an association between high PRL levels and adverse lipid profile [51,53]. Our results are in line with most published studies to date which found amelioration of the lipid profile following DA therapy, although changes have not been observed in all studied lipid parameters. In addition, it has been suggested that TC is one of the first metabolic parameters affected by a decrease in PRL levels following DA therapy [18]. Namely, levels of TC, but not TG, HDL-C or LDL-C, improved at 12 months, with the latter significantly decreasing at 24 months [56]. In particular, changes in TG and LDL-C levels have been attributed to the antilipogenic action in the liver tissue and antilipolytic action in adipose tissue afforded by Das [55]. In line with this finding, prolactinomas were associated with higher BMI and LDL-C [41]. In addition, while gonadotropin replacement didn’t alter patients’ lipid profile, it has been shown that low testosterone levels in men might be associated with decreased HDL-C and high LDL-C and TC levels [57], but this association can be confounded by obesity [58]. While changes in the lipid profile following gonadotropin replacement can be marginal or nonexistent in men [59], the administration of estrogen in women more distinctly decreases LCL-C levels, while increasing HDL-C and TC levels [57,60], although we couldn’t confirm this result.

The reason we did not observe significant improvement in the levels of LDL-C or HDL-C following treatment with DAs or gonadotropin replacement therapy is unclear, as other studies noted a decrease in LDL-C levels with therapy [18]. Reasons may include differences in study characteristics, number of patients included, modalities or doses of gonadal replacement, as well as the risk of bias in uncontrolled studies. Namely, differences in the severity and duration of the diseases and intrinsic and extrinsic factors may influence lipid parameters.

Beside age-specific changes in BMI and metabolic parameters

![Fig. 3. Changes in PRL levels, metabolic parameters and patients’ BMI over the long-term.](image-url)
[61,62], glucocorticoids, thyroxine and statin therapy likewise may affect the lipid profile [63,64]. Namely, while levels of HDL-C are generally increased with glucocorticoids, changes in plasma TG and LDL-C vary considerably [65,66]. Secondary hypothyroidism is known to increase TG, LDL-C, and TG [67]. In addition, statin therapy lowers LDL-C and TC [63]. In the present cohort, the prevalence of pituitary axes deficits—apart from hypogonadism—was not high at baseline or over the long-term. In addition, 6 patients were undergoing statin therapy at last follow-up, and their levels of LDL-C and TC were lower compared to the levels of the other subjects, although not significantly. Thus, it is conceivable that their effect on the metabolic profile may be less strong compared to the long-term control of hyperprolactinemia and associated hypogonadism. However, the small sample size of both subjects on statin therapy and those with pituitary axes deficits other than secondary hypogonadism may fail to reveal a true association.

Study strengths and limitations

The main limitations of our study are its retrospective design, the lack of randomization, and the single-center design. Despite the relatively small number of patients included, which may not reveal a true association between other factors influencing the metabolic profile (i.e., hormonal deficits, statin therapy), a strong point of our study is the collection of data over 20 years, as well as its homogeneity in terms of indications, treatment and follow-up. However, given the long-term follow-up, and there have been advances in the medical treatment and patients’ surveillance over time, which may confound outcomes. In addition, GH may vary the metabolic parameters, but was not systematically measured in this study.

Conclusion

Over the long-term, patients’ BMI and FG improve. However, changes in the metabolic profile are marginal and independent of the primary treatment. It is possible that it is not DAs per se, but rather the management of hyperprolactinemia and hypogonadism that plays a role in patients’ metabolic profile alterations. Considering the clinical significance of obesity and impaired metabolic profile in prolactinoma patients, our results underline the importance of long-term control of hyperprolactinemia.

Funding

No funding was received for this publication.

Declarations

This work is original and has not been published elsewhere nor is it currently under consideration for publication elsewhere.

Ethical standards and patient consent

The Human Research Ethics Committee of Bern (Kantonale Ethikkommission KEK Bern, Bern, Switzerland) approved the project (KEK n° 10-10-2006 and 8-11-2006). The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The assistance of Ms. Jeannie Wurz in editing the manuscript is greatly appreciated.

Contributors

LA contributed to study conception and design, statistical analysis and interpretation, drafting of the manuscript, critical revision and final approval of the article. EC contributed to study conception and design, data interpretation, critical revision and final approval of the article. JF contributed to the acquisition of data, and final approval of the article. RHA, MML, JG, GAS JB, and LM contributed to critical revision and final approval of the article.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jcte.2021.100258.

References

[1] Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013;309:71–82.
[2] Wilding JPH. Endocrine testing in obesity. Eur J Endocrinol 2020;182:C13–5.
[3] Gorvin CM. The prolactin receptor: Diverse and emerging roles in pathophysiology. J Clin Transl Endocrinol 2015;2:85–91.
[4] Shiblī-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary 2009;12:96–104.
[5] Raverot G, Jouanneau E, Trouillas J. Management of endocrine disease: clinical-pathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol 2014;170:R21–32.
[6] Colea A, Di Sarno A, Guerra E, et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 2007;67:426–33.
[7] Kars M, Sourvein PC, Hering RM, et al. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 2009;94:2729–34.
[8] Levy A. Pituitary disease: presentation, diagnosis, and management. J Neuroendocrinol Psychiatry 2004;75(Suppl 3). i47-52.
[9] Andereggen L, Frey J, Andres RH, et al. Long-term follow-up of primary medical versus surgical treatment of prolactinomas in men: effects on hyperprolactinemia, hypogonadism, and bone health. World Neurosurg 2017;97:595–602.
[10] Andereggen L, Frey J, Andres RH, et al. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine 2017;55:223–30.
[11] Donegan D, Atkinson JL, Jentoft M, et al. Surgical outcomes of prolactinomas in recent era: results of a heterogenous group. Endocr Pract 2017;23:37–45.
[12] Tampourou M, Trifanescu R, Paluzzi A, Ahmed SK, Karavitsaki N. THERAPY OF ENDOCRINE DISEASE: surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur J Endocrinol/Eur Feder Endocrine Soc 2016;175:89-96.
[13] Demartini B, Ricciardi L, Ward A, Edwards MJ. Dopamine agonist withdrawal syndrome (DASW) in a patient with a microprolactinoma. J Neurol Neurosurg Psychiatry 2014;85:471.
[14] Moore TJ, Glennmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 2014;174:1930–3.
[15] Honegger J, Nasi-Kordhishti I, Aboutaha N, Giese S. Surgery for prolactinomas: a better choice? Pituitary 2020;23:45–51.
[16] Dekkers OM, Lagro J, Burnman P, Jorgensen JO, Romijn JA, Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonist: systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:43–51.
[17] dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinomas before and after treatment with dopamine agonists. Obesity (Silver Spring) 2011;19:800–5.
[18] Schuetz V, Librizzi R, Trummer C, et al. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas. Metab Brain Dis 2017;32:155–61.
[19] Byberg S, Fattrue J, Andreassen M, Krogh J. Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis. Endocr Connect 2019;8:1395–404.
[20] Freda PU, Wardlaw SL. Clinical review 110: diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 1999;84:3859–66.
[21] Andereggen L, Frey J, Andres RH, et al. First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center. J Endocrinol Invest 2021.
L. Andereggen et al.

Journal of Clinical & Translational Endocrinology 24 (2021) 100258

Do not hallucinate.

[22] Karavitsi N, Thanabalasingham G, Shore HC, et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? a study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol 2006;65:524–9.

[23] Andereggen L, Frey J, Christ E. Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated. Endocrine 2020.

[24] Mehm S, Cananueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273–88.

[25] Saeger W, Ludecke DK, Buchfelder M, Fahrbach R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 2007;156:203–16.

[26] Mezi Z, Grummer-Strawn LM, Pietrobelli A, Goulding A, Goran MI, Dietz WH. Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with prolactinoma. N Engl J Med 2003;349:2023–5.

[27] Andereggen L, Mono ML, Kellner-Weldon F, Christ E. Cluster headache and prolactinoma: Case report of a rare, but potential important causality. J Clin Neurosci 2017;40:62–4.

[28] Knosp E, Knopp M, Wolfsberger S, Kellner-Weldon F. Invasion of the cavernous sinus space in prolactinomas treated with bromocriptine. Eur J Endocrinol 2002;147:77–84.

[29] Raverot G, Wierinckx A, Dantony E, et al. Prognostic factors in prolactin pituitary macroadenoma: Case report of a rare, but potential important causality. J Clin Neurosci 2017;40:62–4.

[30] Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Age-related trends in lipid levels: a large-scale cross-sectional study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabolism. Clin Endocrinol (Oxf) 2007;66:557–64.

[31] Feng L, Nian S, Tong Z, et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 2007;156:203–16.

[32] Andereggen L, Schroth G, Gralla J, et al. Selective inferior petrosal sinus sampling: personal experience and literature review. J Clin Endocrinol Metab 2021;97:987–85.

[33] Andereggen L, Monu ML, Kellner-Weldon F, Christ E. Cluster headache and prolactinoma: Case report of a rare, but potential important causality. J Clin Neurosci 2017;40:62–4.

[34] Andereggen L, Beck J, Gralla J, et al. Selective inferior petrosal sinus sampling: personal experience and literature review. J Clin Endocrinol Metab 2021;97:987–85.

[35] Schristoforidis V, Millas G, Ioannidis A. Discrimination between a role of prolactin and other hormones in body mass index. Endocr Pract 2020.

[36] Doknic M, Pecic S, Zarkovic M, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002;147:77–84.

[37] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[38] Andereggen L, Hess B, Andres E, et al. A ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[39] Andereggen L, Hess B, Andres E, et al. Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas. Sci Rep 2021;11:5122.

[40] Tirosh A, Benbasat C, Shimon I. Short-term decline in prolactin concentrations can predict future prolactin normalization, tumor shrinkage, and time to remission in men with macroadenomas. Endocr Pract 2015;21:1240–7.

[41] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[42] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[43] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[44] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[45] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[46] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[47] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[48] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[49] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[50] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[51] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[52] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[53] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[54] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[55] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[56] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[57] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[58] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[59] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[60] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[61] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[62] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[63] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[64] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[65] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.

[66] Andereggen L, Hess B, Andres E, et al. Ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018;148:w14521.